in this issue
Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients
Teva to Buy Merck KGaA’s Generics?
1:50 PM MDT | July 26, 2007 | Chemical Week Editorial Staff
Teva Pharmaceutical Industries (Petach Tikva, Israel) is likely to be selected to acquire Merck KGaA’s generic pharmaceutical business, sources say. Merck KGaA invited offers for the business but says it has not made a final decision to divest. Aggressive bidding had pushed the price of the generics business up to €4 billion-€5 billion ($5.5 billion-$6.8 billion) by the close of a revised round of bids on April 30, sources add. The other bidders are reportedly Mylan (Canonsburg, PA), and a joint offer by private equity firms Apax Partners and Bain...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee